Lucid Diagnostics Inc. · NASDAQ:LUCD

Lucid Diagnostics — Q3 2026 Earnings Presentation

15 slides from Lucid Diagnostics's earnings presentation, Nov 12, 2026

  1. Slide 1: Q3 2026 Business Update

    Nasdaq: LUCD Q3 2026 Business Update November 12, 2026 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO

  2. Slide 2: Disclaimer

    Disclaimer ▪ This presentation may contain certain forward-looking statements related to Lucid Diagnostics Inc. (the “Company”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors that

  3. Slide 3: Lishan Aklog, M.D. Chairman & CEO

    Lishan Aklog, M.D. Chairman & CEO

  4. Slide 4: Medicare accepted for at-risk patients

    Medicare accepted for at-risk patients Submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate of $1,938.01 per test.

  5. Slide 5: Commercial Execution

    Commercial Execution Commercial transition focused on Medicare population Very strong early momentum Laboratory, manufacturing and personnel capacity not a limiting factor Recent financing provide sufficient runway Near- and medium-term commercial expansion plans 5

  6. Slide 6: Revenue Opportunity

    Revenue Opportunity $1,938 × ~30M = Medicare rate per test At-risk patients recommended for screening ~$60B Total addressable U.S. market

  7. Slide 7: Business Update

    ms (b) Lucid diagnostics Business Update

  8. Slide 8: Market Access & Commercialization

    Market Access & Commercialization CPT | ICD-10 Medicare Billing & Coding Commercial Coverage AGA Guidelines & Evidence Veterans Affairs 8

  9. Slide 9: Q3 2026 Financial Update

    Q3 2026 Financial Update Dennis McGrath, CFO

  10. Slide 10: Balance Sheet

    Balance Sheet ($ in thousands) 3Q26 2Q26 Change Assets Cash $17,993 $33,404 $(15,411) Fixed Assets $706 $810 $(104) All other Assets $9,158 $4,732 $4,426 Liabilities Accounts Payable $1,013 $667 $346 Senior Secured Convertible Notes $17,300 $23,500 $(6,200) Other Current Liabilities $3,333 $3,349 $(

  11. Slide 11: P&L

    P&L ($ in thousands) 3Q26 3Q25 Change 3Q26 - YTD 3Q25 - YTD Change Revenue $1,203 $1,211 $(8) $3,932 $3,202 $730 Operating Expenses $13,479 $12,970 $509 $41,122 $38,831 $2,291 Net Loss $(6,677) $(10,397) $3,720 $(32,273) $(41,744) $9,471 1 2 EBITDA $(6,509) $(10,276) $3,767 $(31,797) $(41,341) $9,54

  12. Slide 12: Non-GAAP Operating Expense

    Non-GAAP Operating Expense 8,000 16,000 14,139 7,000 14,000 12,328 11,511 11,709 6,000 11,802 12,000 5,000 10,000 4,000 8,000 3,000 6,000 2,000 4,000 1,000 2,000 0 0 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Cost of Revenue Sales and Marketing General & Admin R&D Total To supplement our unaudited fina

  13. Slide 13: EsoGuard Revenue & Test Volume

    EsoGuard Revenue & Test Volume 60,000 $160,000,000 $140,000,000 50,000 50,000+ Cumulative EsoGuard Tests Performed Since Launch $120,000,000 40,000 $100,000,000 30,000 $80,000,000 $60,000,000 20,000 $40,000,000 10,000 $20,000,000 - $0 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25

  14. Slide 14: Q&A

    Q&A

  15. Slide 15: Closing Remarks

    ms (b) Lucid diagnostics Closing Remarks

Lucid Diagnostics — Q3 2026 Earnings Presentation on 6ix